Key Drivers of Coagulation Factor Use in Von Willebrand Disease During Hospitalization: An Overview of the French BERHLINGO Cohort.
Valérie HorvaisPhilippe BeurrierVincent CussacBrigitte Pan-PeteschSolène Schirr-BonnansJohann RoseSophie BayartCatherine TernisienMarc FouassierMarianne SigaudAntoine BabutyNicolas DrillaudPhilippe GautierMarc Trossaërtnull nullPublished in: Clinical drug investigation (2023)
The use of VWF concentrates is mostly influenced by low basal levels of VWF and FVIII, but also by VWD type or the cause for hospitalisation. These results could inform future studies of newly released recombinant VWF.
Keyphrases